TPM® Enhances Cannabinoid Bioavailability in Comparative Canine Study
Avecho has today shared interim results from a comparative canine study showing that Avecho’s oral cannabidiol (CBD) product under development has increased bioavailability compared to Epidiolex®, the only FDA approved CBD product.
Early results from the study, which are being conducted in the UK, also demonstrate increased cannabidiol (CBD) bioavailability after administration of Avecho’s TPM® directly to Epidiolex. Pleasingly, despite the four-times increase in average CBD absorption, no increases in gastrointestinal irritation were observed.
Avecho CEO, Dr Paul Gavin said:
“We have previously shown that our proprietary TPM® formulations could increase the oral absorption of CBD in rats when compared to simple CBD oil formulations currently prescribed to patients in Australia. These formulations are now in clinical trials and will be entering Phase III clinical trials for an insomnia related indication.”